A 6-week, double-masked, paralle-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension

Clinical Therapeutics

Volumn 28, Issue 3, 2006, Pages 332-339

  Franks, Wendy A ^a   Renard, Jean P ^b   Cunliffe, Ian A ^c   Rojanapongpun, Prin ^d  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b University of Paris Descartes   (France)

^c Birmingham Heartlands and Solihull Hospitals   (United Kingdom)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

glaucoma; intraocular pressure; latanoprost; prostaglandin; timolol; travoprost

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LATANOPROST; PLACEBO; PROSTAGLANDIN; TIMOLOL; TRAVOPROST;

ABNORMAL VISION; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DACRYOCYSTITIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISCHARGE; EYELID EDEMA; EYELID ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PIGMENTATION; PSEUDOEXFOLIATION; RACE DIFFERENCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCREENING; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TONOMETRY;

AGED; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 33646892613     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.03.001     Document Type: Article

References (33)

1. Van der Valk R., Webers C.A., Schouten J.S., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185
2. Griffin B.W., Williams G.W., Crider J.Y., and Sharif N.A. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study. J Pharmacol Exp Ther 281 (1997) 845-854
3. Sharif N.A., Kelly C.R., Crider J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and otherPG receptors in cultured cells. J Ocul Pharmacol Ther 19 (2003) 501-515
4. Sharif N.A., Crider J.Y., Husain S., et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: Phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther 19 (2003) 437-455
5. Sharif N.A., Kelly C.R., and Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 44 (2003) 715-721
6. Gabelt B.T., and Kaufman P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49 (1989) 389-402
7. Nilsson S.F., Samuelsson M., Bill A., and Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgusmonkey. Exp Eye Res 48 (1989) 707-716
8. Crawford K., and Kaufman P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol 105 (1987) 1112-1116
9. Camras C.B. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res 23 (1995) 519-525
10. Snowbird, Utah. Toris C.B., Camras C.B., Zhan G., et al. Effect of travoprost on diurnal and nocturnal aqueous humor dynamics in patients with ocular hypertension and glaucoma. Poster presented at: American Glaucoma Society 15th Annual Meeting (March 3-6, 2005)
11. Wiederholt M., Thieme H., and Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 19 (2000) 271-295
12. Weinreb R.N., Kashiwagi K., Kashiwagi F., et al. Prostaglandins increase matrix metal Ioproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38 (1997) 2772-2780
13. Poser J.F., Millar C., and Kaufman P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 36 (1995) 2461-2465
14. Alphen G.W., Wilhelm P.B., and Elsenfeld P.W. The effect of Prostaglandins on the isolated internal muscles of mammalian eye, including man. Doc Ophthalmol 42 (1977) 397-415
15. Coakes R.L., and Brubaker R.F. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 96 (1978) 2045-2048
16. Crider J.Y., and Sharif N.A. Adenylyl cyclase activity mediated by beta-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J Ocul Pharmacol Ther 18 (2002) 221-230
17. Camras C.B., Alm A., Watson P., Stjernschantz J., and Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 103 (1996) 1916-1924
18. Zimmerman T.J., and Kaufman H.E. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95 (1977) 601-604
19. Dubiner H.B., Sircy M.D., Landry T., et al. Comparison ofthe diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 26 (2004) 84-91
20. Netland P.A., Landry T., Sullivan E.K., et al., Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glauco ma or ocular hypertension. Am J Ophthalmol 132 (2001) 472-484
21. Przydryga J.T., Egloff C., and Swiss Start Study Group. Intraocular pressure lowering efficacy of travo prost. Eur J Ophthalmol 14 (2004) 416-422
22. Available at:. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Accessed (January 25, 2006). http://www.net/e/policy/b3.htm
23. Travatan (2004), Alcon Laboratories, Fort Worth, Tex
24. Xalcom (2005), Pfizer, New York, NY
25. Konstas A.G., Nakos E., Tersis I., et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 133 (2002) 753-757
26. Konstas A.G., Boboridis K., Tzetzi D., et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 123 (2005) 898-902
27. Diestelhorst M., Larsson L.I., and European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients withopen angle glaucoma and ocular hypertension. Br J Ophthalmol 88 (2004) 199-203
28. Diestelhorst M., and Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol 236 (1998) 577-581
29. Nelson W.L., Fraunfelder F.T., Sills J.M., et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 102 (1986) 606-611
30. Alm A., and Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol.Scandinavian Latanoprost Study Group. Ophthalmology 102 (1995) 1743-1752
31. [published correction appears in Lancet. 1995;346: 322]. Diggory P., Cassels-Brown A., Vail A., et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 345 (1995) 1604-1606
32. Diggory P., and Franks W. Medical treatment of glaucoma-a reappraisal of the risks. Br J Ophthalmol 80 (1996) 85-89
33. Pache M., Dubler B., and Flammer J. Peripheral vasospasm and nocturnal blood pressure dipping-two distinct risk factors for glaucomatous damage?. Eur J Ophthalmol 13 (2003) 260-265